

Iconovo strengthens patent protection for ICORES® in the EU

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that the European Patent Office (EPO) intends to approve Iconovo's application for yet another patent for the inhalation platform ICORES®. ICORES® is already being used in several of Iconovo's customer projects, and this new patent strengthens the intellectual property rights, benefiting customers who will launch pharmaceutical products based on the company's unique inhaler in the future.

The European Patent Office has issued an Intention to Grant for a patent application related to ICORES®, which means that Iconovo will receive strengthened patent protection for the inhaler in Europe until 2040 after a series of administrative steps. ICORES® is already protected by patents in Europe (EPO), Sweden, India, China, and the USA.

"The preliminary notification from the European Patent Office strengthens our intellectual property rights in Europe and enhances the value of our product portfolio. This additional patent provides our customers with additional market exclusivity and extended patent protection after the launch of ICORES® in the European market," says Roger Lassing, Vice President of Business Development at Iconovo.

About ICORES

ICORES is a flexible multi-dose dry powder inhaler with feedback features developed by Iconovo. ICORES is a reservoir inhaler similar in handling to AstraZeneca's best-selling Turbuhaler®. It features two separate reservoirs which allow for simultaneous inhalation of two different formulations that makes it suitable for combination products. Its intuitive handling, exact dose counting, and clear inhalation feedback helps the patient to stay compliant with the treatment. ICORES is ready for commercial manufacturing making it the best alternative for pharmaceutical companies seeking a reservoir inhaler.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

Attachments

[Iconovo strengthens patent protection for ICORES® in the EU](#)